1. Home
  2. ENPH vs TVTX Comparison

ENPH vs TVTX Comparison

Compare ENPH & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enphase Energy Inc.

ENPH

Enphase Energy Inc.

N/A

Current Price

$38.63

Market Cap

5.5B

Sector

Technology

ML Signal

N/A

Logo Travere Therapeutics Inc.

TVTX

Travere Therapeutics Inc.

N/A

Current Price

$65.62

Market Cap

5.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ENPH
TVTX
Founded
2006
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
5.3B
IPO Year
2011
2013

Fundamental Metrics

Financial Performance
Metric
ENPH
TVTX
Price
$38.63
$65.62
Analyst Decision
Hold
Strong Buy
Analyst Count
23
13
Target Price
$41.30
$40.62
AVG Volume (30 Days)
4.3M
1.6M
Earning Date
04-28-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
72.00
92.89
EPS
N/A
N/A
Revenue
$1,472,985,000.00
N/A
Revenue This Year
N/A
$44.76
Revenue Next Year
$9.81
$35.51
P/E Ratio
N/A
N/A
Revenue Growth
10.72
N/A
52 Week Low
$25.78
$17.05
52 Week High
$73.74
$66.24

Technical Indicators

Market Signals
Indicator
ENPH
TVTX
Relative Strength Index (RSI) 44.45 67.55
Support Level $34.69 $53.76
Resistance Level $42.96 $66.24
Average True Range (ATR) 1.90 2.47
MACD 0.14 0.41
Stochastic Oscillator 21.21 95.72

Price Performance

Historical Comparison
ENPH
TVTX

About ENPH Enphase Energy Inc.

Enphase Energy is a global energy technology company. It delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Enphase derives a majority of revenue from the United States.

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

Share on Social Networks: